




Healthcare Industry News: Cardiac Resynchronization Therapy
News Release - March 15, 2011
Heart Force Medical Inc. Acquires Patent
VANCOUVER, BC, March 15, 2011--(Healthcare Sales & Marketing Network)--Heart Force Medical Inc., a Vancouver-based company that has developed a non-invasive cardiac assessment, monitoring and screening device is pleased to announce that it has acquired from Dr. Frank Marcus his ownership of US Patent No. 6978184 titled Optimization Method for Cardiac Resynchronization Therapy.Dr. Marcus is the Chair of Heart Force Medical’s Clinical Advisory Board and will be receiving his compensation equally in both cash and shares of Heart Force Medical.
“With our commercialization strategy focused around Cardiac Resynchronization Therapy the acquisition of this patent is a key element that allows us to build a strong business in this market,” said Dr. Geoff Houlton, President, CEO and Chief Medical Officer of Heart Force.
About Heart Force:
Heart Force Medical Inc. (HFM), a private company, has invented and holds patents for the digital Ballistocardiograph (dBG™). The dBG 300, which is already approved in Canada and the United States, captures the movement of the heart during each cardiac cycle (heart beat). These movements (acceleration and force) are sensed by an accelerometer aligned to the three principal axes and displayed on a computer screen using HFM’s proprietary software. Preliminary evaluation has determined that a 10-30 second recording of the dBG waveform is sufficient for a detailed analysis of cardiac performance. The Heart Force dBG 300 device is a non-invasive, standalone, portable unit and contains sophisticated digital sensors and proprietary software.
For more information: visit www.heartforcemedical.com or contact:
Geoff Houlton, President, CEO and Chief Medical Officer
geoff.houlton@heartforcemedical.com
Direct: 604 566-8202
Issa Nakhleh, CFO
issa.nakhleh@heartforcemedical.com
Direct: 604 566-8206
Source: Heart Force Medical
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.